secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001493152-25-026383
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity receives FDA warning letter over Interfyl marketing claims
---------------------------------------------------------------------

- FDA warning letter received Dec 1, 2025, regarding marketing material for Interfyl (human connective tissue matrix).
- Letter cites outcome-based and metabolic activity claims; company must limit such claims per Section 361 of CFR 1271.10.
- No restriction on manufacturing, product shipment, recall, or ability to seek 510(k) clearance.
- Company states no material impact on operational/financial expectations; resolution timeline uncertain.
- Additional regulatory action may occur if issues not resolved to FDA's satisfaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315225026383/0001493152-25-026383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315225026383/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-026383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer